Targeting HPV16 E6 Oncoprotein in Head and Neck Cancer
Author Information
Author(s): Harris Matthew, Wang Xing Guo, Jiang Zewei, Goldberg Gary L, Casadevall Arturo, Dadachova Ekaterina
Primary Institution: Albert Einstein College of Medicine
Hypothesis
Can radioimmunotherapy effectively target HPV16 E6 oncoprotein in head and neck squamous cell carcinoma?
Conclusion
The study demonstrates the potential of radioimmunotherapy as a novel treatment for HPV-positive head and neck squamous cell carcinoma.
Supporting Evidence
- The novel HPV16+ 2A3 cell line reliably expressed E6 oncoprotein.
- E6 expression was modifiable with proteasome inhibitor MG132.
- The 2A3 cell line preserved 100% tumorigenicity of parent FaDu cells in nude mice.
- 200 μCi 188Re-C1P5 mAb was effective in decreasing tumor growth compared to untreated controls.
Takeaway
Researchers created a new cell line from a common cancer type to test a special treatment that targets a virus linked to some cancers, showing it can help shrink tumors.
Methodology
The study involved creating a new HPV16+ cell line and testing radioimmunotherapy in mice with tumors.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses.
Participant Demographics
Nude mice were used for the experiments.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website